Novel therapeutic approach by culture filtrate of Cryptococcus neoformans var. gattii (CneF) in experimental immune complex glomerulonephritis.
The present study was undertaken to determine the therapeutic effect of the culture filtrate of Cryptococcus neoformans var. gattii (CneF) in experimental immune complex glomerulonephritis. Bovine serum albumin (BSA) nephritis was induced in rats by a subcutaneous immunization and daily intravenous administration of BSA. CneF solution at three different doses (36, 54, and 90 mg/kg based on carbohydrate concentration) was administered intraperitoneally at regular 72-h intervals for 4 weeks. Onset of treatment was day 65, and urinary protein was measured at different intervals. Animals were euthanized on day 107. Serum and urine determinants were measured at the time of sacrifice and kidney specimens were examined. Results of this experiment showed that CneF therapy could significantly reduce the urinary protein excretion, blood urea nitrogen (BUN), plasma concentration of triglyceride, and increase the serum HDL cholesterol in treated rats vs. nontreated controls. Moreover, there was significant difference in glomerular changes between treated and nontreated groups. These observations show that the beneficial effect of CneF may be related to decreased number of glomerular leukocytes. Our findings suggest that treatment with CneF as a new antiinflammatory compound can reduce proteinuria, suppress the development of glomerular lesions, and exert lipid-lowering property in a rat model of immune complex glomerulonephritis.
Mirshafiey
A
A
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, P.O. Box 6446, 14155, Tehran, Iran. mirshafiey_tums_edu_ir@yahoo.com
Mehrabian
F
F
Razavi
A
A
Shidfar
M R
MR
Namaki
S
S
D000818:Animals; D003455:Cryptococcus neoformans / Q000276:immunology*; D004195:Disease Models, Animal; D005260:Female; D005921:Glomerulonephritis / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007105:Immune Complex Diseases / Q000628:therapy*; D007668:Kidney / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D011134:Polysaccharides / Q000008:administration & dosage* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D012107:Research Design
D008055:Lipids; D011134:Polysaccharides; C027478:glucuronoxylomannan